Unlike contrast agents for MRIs, which rely on blood-brain barrier disruption and may be influenced by tumor microenvironment changes, FET uptake is mediated through the LAT1 transporter and reflects active glioma metabolism, regardless of MGMT status (Miyagawa et al., 1998; Habermeier et al., 2015). The gene discussed is MGMT; the disease is central nervous system cancer.